Left Ventricular Assist Devices Market Report 2025

The left ventricular assist devices market size has grown strongly in recent years. It will grow from $1.6 billion in 2024 to $1.74 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to post-market surveillance and data, reduction in device size and noise, awareness and education programs, increased physician experience, and adoption in bridge therapy.

The left ventricular assist devices market size is expected to see strong growth in the next few years. It will grow to $2.52 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to expanded indications, a rise in heart failure cases, enhanced patient outcomes, market approval and regulatory changes, focus on destination therapy. Major trends in the forecast period include advancements in implantation techniques, development of dual-pump systems, growing use as a destination therapy, focus on minimizing infection risks, integration with heart failure management programs, and improved anticoagulation management.

The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the left ventricular assist device market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including coronary heart disease and congenital heart disease, among others. In cases of advanced heart failure, a left ventricular assist device supports the heart's left ventricle, which is responsible for pumping blood to the body’s tissues. For example, in March 2024, data released by the Office for Health Improvement and Disparities, a UK government agency, indicated that there were over 1,862,500 individuals (3%) diagnosed with coronary heart disease (CHD) in England in 2023. Additionally, in December 2022, data from the New York government revealed that heart disease is responsible for approximately 697,000 deaths annually in the United States, equating to 1 in every 5 fatalities. Each year, around 805,000 Americans experience a heart attack, with 605,000 being their first and 200,000 resulting from previous heart attacks. Therefore, the rising prevalence of cardiovascular diseases is fueling the growth of the left ventricular assist device market.

The increase in healthcare expenditures is expected to drive the growth of the left ventricular assist device market in the future. Healthcare expenditures encompass all costs related to providing health services, family planning activities, nutrition programs, and emergency assistance with a focus on health. Higher healthcare spending can facilitate the advancement and development of various health-related products, including left ventricular assist devices. As healthcare expenditures rise, they will positively impact the growth of the left ventricular assist device market. For example, in 2022, the Office for National Statistics, a UK national statistics organization, reported that healthcare expenditure in the UK reached approximately $354.88 billion (£283 billion), reflecting a nominal increase of 0.7% compared to spending in 2021. Thus, the rise in healthcare expenditures is propelling the growth of the left ventricular assist device market.

Leading companies in the left ventricular assist devices market are focusing on developing technologies like power management units (PMUs) to improve the efficiency, reliability, and longevity of these devices. A power management unit (PMU) is an integrated circuit responsible for regulating and managing the power supply and distribution to various components within electronic devices. For example, in June 2022, Renesas Electronics, a semiconductor manufacturer based in Japan, introduced the SmartBond DA1470x. This family of products marks a significant advancement in Bluetooth Low Energy (BLE) technology, offering developers a versatile platform for creating innovative IoT products while optimizing costs and enhancing performance. The high level of integration in the SmartBond DA1470x simplifies design, boosts reliability, and shortens time-to-market across various applications.

Major companies in the left ventricular assist device industry are significantly investing in research, development, and early feasibility trials for their Total Artificial Heart (TAH). This substantial investment aligns with long-term goals, as demonstrated by BiVACOR, a US-based medical technology company that secured $18 million in funding for TAH development in March 2023. Led by Cormorant Asset Management and OneVentures, these funds will support research, early feasibility trials, and key executive hires. The BiVACOR TAH, designed for severe biventricular heart failure, incorporates advancements from Left Ventricular Assist Device (LVAD) technology, signaling a shift toward durable rotary blood pumps.

In December 2022, Johnson & Johnson, a prominent US-based pharmaceutical and medical technology company, completed the acquisition of Abiomed Inc for $16.6 billion. This strategic acquisition aimed to expand Johnson & Johnson's presence in the high-growth cardiovascular markets. Abiomed Inc., a US-based medical device technology company, specializes in providing circulatory and oxygenation support devices, including ventricular assist technology that pumps blood from the left ventricle (LV).

Major companies operating in the left ventricular assist devices market include Abbott Laboratories, Medtronic plc., Terumo Corporation, St. Jude Medical, MAQUET GmbH & Co., LivaNova Plc, Thoratec Corporation, Abiomed Inc, Transonic Systems, Berlin Heart GmbH, BioVentrix, Cleveland Heart Inc., Jarvik Heart Inc., CorWave SA, SynCardia Systems LLC, NuPulseCV Inc., Fineheart, Procyrion Inc, Carmat SA, BiVACOR Inc, Cardiac Assist Inc., Leviticus Cardio Ltd., AdjuCor GmbH, Calon Cardio-Technology Ltd, Evaheart Inc., Sunshine Heart Inc., CH Biomedical Inc., Sun Medical Technology Research Corp.

North America was the largest region in the left ventricular assist devices market in 2024. The regions covered in the left ventricular assist devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the left ventricular assist devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A left ventricular assist device (LVAD) serves as a mechanical pump implanted in heart failure patients, assisting the heart's lower left chamber (left ventricle) in pumping blood to the aorta and throughout the body.

The primary types of left ventricular assist devices include transcutaneous left ventricular assist devices and implantable left ventricular assist devices. A transcutaneous left ventricular assist device is characterized by having both an external power supply and an internal pump located inside the body. Tubes connect the pump to the heart through small openings in the abdomen. This type of LVAD is often employed for short-term support during or following surgery. Left ventricular assist devices can have either pulsatile or non-pulsatile flows, and they are used in various therapeutic approaches such as bridge-to-recovery (BTR) therapy, bridge-to-transplant (BTT) therapy, destination therapy, and bridge-to-candidacy (BTC) therapy. Cardiology centers and hospitals typically utilize these devices for patient care.

The left ventricular assist devices market research report is one of a series of new reports that provides left ventricular assist devices market statistics, including the left ventricular assist devices industry's global market size, regional shares, competitors with a left ventricular assist devices market share, detailed left ventricular assist devices market segments, market trends, and opportunities, and any further data you may need to thrive in the left ventricular assist devices industry. This left ventricular assist devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The left ventricular assist devices market consists of sales of rechargeable left ventricular assist devices, non-rechargeable left ventricular assist devices, heart pumps, and controllers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.